Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Restructuring: 2009-2013

Historic Cash from Restructuring for Cytokinetics (CYTK) over the last 3 years, with Sep 2013 value amounting to -$636,000.

  • Cytokinetics' Cash from Restructuring fell 200.00% to -$636,000 in Q3 2013 from the same period last year, while for Sep 2013 it was $1.3 million, marking a year-over-year decrease of 33.92%. This contributed to the annual value of -$56,000 for FY2012, which is 128.87% down from last year.
  • According to the latest figures from Q3 2013, Cytokinetics' Cash from Restructuring is -$636,000, which was down 200.00% from $636,000 recorded in Q2 2013.
  • Cytokinetics' Cash from Restructuring's 5-year high stood at $797,483 during Q1 2011, with a 5-year trough of -$785,991 in Q4 2010.
  • Moreover, its 3-year median value for Cash from Restructuring was $636,000 (2013), whereas its average is $453,680.
  • Per our database at Business Quant, Cytokinetics' Cash from Restructuring spiked by 2,200.72% in 2010 and then plummeted by 200.00% in 2013.
  • Over the past 5 years, Cytokinetics' Cash from Restructuring (Quarterly) stood at -$18,049 in 2009, then spiked by 2,200.72% to -$785,991 in 2010, then soared by 188.04% to $692,000 in 2011, then dropped by 8.09% to $636,000 in 2012, then plummeted by 200.00% to -$636,000 in 2013.
  • Its Cash from Restructuring stands at -$636,000 for Q3 2013, versus $636,000 for Q2 2013 and $636,000 for Q1 2013.